As the cannabis sector continues to push forward, or should we say fall down, earnings season has arrived once again. So far, we have seen mid-cap licensed producers, like Aphria and OrganiGram, report decent earnings. Next up is Canopy Growth (CGC), which…
Is GW Pharmaceuticals Stock a Buy?
GW Pharmaceuticals (NASDAQ:GWPH) hit paydirt when its crown jewel — Epidiolex — became the first cannabidiol-derived drug approved by the U.S. Food and Drug Administration (FDA). Epidiolex is a treatment for seizures in patients with Lennox-Gastaut syndrome (LGS) and Dravet syndrome, both…
This Pot Stock Is Up Around 50% in 3 Months. Can It Continue Soaring?
Marijuana stocks are still struggling to start 2020, with the Horizons Marijuana Life Sciences ETF up just 2% since the beginning of the new year. Many companies are low on cash and a lack of profitability is only making investors even more…
Aurora Cannabis (ACB) Makes a Big Announcement and it’s Shares Plummet
Investors in Aurora Cannabis (ACB) can’t catch a break. Aurora Cannabis’ stock was rallying at the beginning of this week off of news that the company had licensed their third EU-GMP facility and following a two-month suspension of medical marijuana…
2 Best Cannabis Stocks to Buy in February
Not a whole lot has gone right for the legal cannabis industry over the past 10 months. Valuations across the space have absolutely cratered during this period thanks to a suite of headwinds such as burdensome tax rates, a stubbornly…
Better Buy: Aurora Cannabis (ACB) vs. Aphria (APHA)
If you’re looking to invest in the cannabis market, now’s definitely a tough time, with most large-cap pot stocks witnessing significant losses over the past 12 months. Coupled with the fact that the majority of them are still struggling to…
